BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 17369780)

  • 1. [Tumor markers useful in the diagnostics and monitoring of endometrial and cervical cancer].
    Bedkowska GE; Lawicki S; Szmitkowski M
    Postepy Hig Med Dosw (Online); 2007; 61():122-8. PubMed ID: 17369780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New tumour markers useful in diagnostics and monitoring of cervical cancer].
    Bedkowska GE; Lawicki S; Szmitkowski M
    Przegl Lek; 2007; 64(12):1022-7. PubMed ID: 18595508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Molecular markers of carcinogenesis in the diagnostics of cervical cancer].
    Bedkowska GE; Ławicki S; Szmitkowski M
    Postepy Hig Med Dosw (Online); 2009 Feb; 63():99-105. PubMed ID: 19252468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating tumor markers in gynecological tumors.
    Rustin GJ
    Curr Opin Oncol; 1996 Sep; 8(5):426-31. PubMed ID: 8914810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Tumor markers of breast cancer].
    Sławicki S; Mroczko B; Szmitkowski M
    Postepy Hig Med Dosw (Online); 2004 Jul; 58():292-300. PubMed ID: 15280799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The clinical usefulness of SCC antigen for diagnosis of recurrent cervical squamous cancer].
    Umezawa S; Takeshima N; Shimizu Y; Hasumi K
    Nihon Sanka Fujinka Gakkai Zasshi; 1995 Feb; 47(2):165-8. PubMed ID: 7706858
    [No Abstract]   [Full Text] [Related]  

  • 7. Cervical cancer: Biomarkers for diagnosis and treatment.
    Dasari S; Wudayagiri R; Valluru L
    Clin Chim Acta; 2015 May; 445():7-11. PubMed ID: 25773118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early predicting recurrent cervical cancer with combination of tissue polypeptide specific antigen (TPS) and squamous cell carcinoma antigen (SCC).
    Hung YC; Shiau YC; Chang WC; Kao CH; Lin CC
    Neoplasma; 2002; 49(6):415-7. PubMed ID: 12584591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYFRA 21-1, TPA-M, TPS, SCC-Ag and CEA in patients with squamous cell lung cancer and in chemical industry workers as a reference group.
    Kulpa J; Wójcik E; Radkowski A; Kolodziejski L; Stasik Z
    Anticancer Res; 2000; 20(6D):5035-40. PubMed ID: 11326663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen.
    Bonfrer JM; Gaarenstroom KN; Korse CM; Van Bunningen BN; Kenemans P
    Anticancer Res; 1997; 17(3C):2329-34. PubMed ID: 9245246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Squamous cell carcinoma (SCC)--nature and usage in patients with cervical carcinoma].
    Bocheva Y; Bochev P; Chaushev B; Ivanov S
    Akush Ginekol (Sofiia); 2015; 54(2):29-34. PubMed ID: 25909138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Determination of the SCC antigen in the serum of patients with cervical cancer].
    Crombach G; Würz H; Bolte A
    Geburtshilfe Frauenheilkd; 1987 Jul; 47(7):439-45. PubMed ID: 3623046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pattern of failure and value of follow-up procedures in endometrial and cervical cancer patients.
    Sartori E; Pasinetti B; Carrara L; Gambino A; Odicino F; Pecorelli S
    Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S241-7. PubMed ID: 17826824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum squamous cell carcinoma antigen in gynecologic malignancies with special reference to cervical cancer.
    Hsieh CY; Chang DY; Huang SC; Yen ML; Juang GT; Ouyang PC
    Taiwan Yi Xue Hui Za Zhi; 1989 Aug; 88(8):797-800. PubMed ID: 2592943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature.
    Gadducci A; Tana R; Cosio S; Genazzani AR
    Crit Rev Oncol Hematol; 2008 Apr; 66(1):10-20. PubMed ID: 17964182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Tumor markers in the early diagnosis of recurrence in gynecologic neoplasms: combined determination of CA-125, CA 15-3, CA 72.4, SCC, 90 K].
    Garzetti GC; Di Lauro RM; Ciavattini A; Pallotta MR; Marchegiani F; Valensise H; Tranquilli AL; Arduini D; Romanini C
    Ann Ostet Ginecol Med Perinat; 1991; 112(5):320-3. PubMed ID: 1817444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diffusion-weighted imaging and dynamic contrast-enhanced MRI in assessing response and recurrent disease in gynaecological malignancies.
    Hameeduddin A; Sahdev A
    Cancer Imaging; 2015 Mar; 15(1):3. PubMed ID: 25889065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of Cyfra 21-1, TPA, and SCC-Ag in predicting extracervical disease and prognosis in cervical cancer.
    Gaarenstroom KN; Bonfrer JM; Korse CM; Kenter GG; Kenemans P
    Anticancer Res; 1997; 17(4B):2955-8. PubMed ID: 9329574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring endometrial adenocarcinoma with a four tumor marker combination. CA 125, squamous cell carcinoma antigen, CA 19.9 and CA 15.3.
    Matorras R; Rodríguez-Escuderoi FJ; Diez J; Genollá J; Cruz Fombellida J; Ruibal A
    Acta Obstet Gynecol Scand; 1992 Aug; 71(6):458-64. PubMed ID: 1326844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The plasma levels and diagnostic utility of stem cell factor (SCF) and macrophage-colony stimulating factor (M-CSF) in cervical cancer patients].
    Lawicki S; Bedkowska E; Gacuta-Szumarska E; Knapp P; Szmitkowski M
    Pol Merkur Lekarski; 2008 Jul; 25(145):38-42. PubMed ID: 18839612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.